Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc has 133.73M shares outstanding.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc maintains a current ratio of 3.05, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 93.60, indicating elevated leverage, while an interest coverage ratio of 3.24 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc posted a return on equity (ROE) of 100.70, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 15.96, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.73M in revenue per employee across its workforce of 2,432.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 11.58 indicates how many times Alnylam Pharmaceuticals, Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc recorded an income tax benefit of -7.37M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 699.86M, leaving 707.23M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc generated 4.21B in revenue and converted that into 707.23M in net income, yielding earnings per share of 5.14. EBITDA reached 923.04M, while operating income came in at 875.10M.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc holds 2.90B in cash and equivalents against 1.11B in total debt, resulting in a net debt position of -610.38M. Total book value stands at 1.19B, with working capital of 2.72B providing operational flexibility.

Alnylam Pharmaceuticals, Inc produced 798.11M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -80.48M in capital expenditures, free cash flow totaled 717.63M - equivalent to 5.41 per share.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc posted a gross margin of 79.65, reflecting its pricing power and cost economics. The operating margin of 20.81 and net profit margin of 16.82 provide insight into operational efficiency.